Bone marrow stem cells (BMAC)

What are bone marrow stem cells and BMAC?

There are different cell types in the bone marrow. Mesenchymal stromal cells (MSCs) are particularly relevant for orthopedic applications. They contribute to the regulation of inflammatory processes and tissue healing via messenger substances (paracrine effects). In practice, a single cell type is usually not isolated, but rather a prepared bone marrow concentrate (BMAC) is used - an autologous, minimally manipulated cell suspension that, in addition to MSC, also contains other blood and progenitor cells, growth factors and cytokines.

• Mesenchymal stromal cells (MSC): support healing and modulation of inflammation
• Hematopoietic cells: precursors of blood cells, contained in BMAC
• Growth factors/cytokines: biologically active signaling proteins
• BMAC: patient's own (autologous) concentrate, without cell culture/expansion

Important: In our practice we do not use any cell culture process with expansion. Only the patient's own bone marrow concentrate, prepared under sterile conditions, is used.

When can treatment make sense?

BMAC treatment can be an option in selected cases - especially if conservative measures have been consistently exhausted and a relevant limitation still exists. The decision is made after thorough diagnostics, indication testing and information.

• Early to moderate osteoarthritis (e.g. knee, hip, ankle) with persistent symptoms despite physio, weight management and joint-gentle activity
• Circumscribed cartilage lesions (focal, not extensive), e.g. B. in the knee
• Chronic tendinopathies (e.g. Achilles tendon, patellar tendon, tennis elbow) when other conservative therapies do not help sufficiently
• Accompanying cartilage or ligament-preserving procedures as an additive measure (in individual cases)

Experience has shown that the effectiveness of biological injections is limited in advanced osteoarthritis with pronounced joint space narrowing, severe axial misalignment or instability. Then operational options should be examined.

Evidence brief

Studies on BMAC show promising improvements in pain and function, particularly in mild to moderate osteoarthritis and some tendinopathies. However, the database is heterogeneous: protocols, cell numbers, preparation and indications differ. For knee osteoarthritis, meta-analyses indicate possible advantages over placebo or hyaluronic acid, in some cases comparable to PRP. However, long-term data, standardized procedures and robust, independent studies are lacking to provide clear guideline recommendations.

• Potential: Pain relief and functional gain in selected indications
• Uncertainties: optimal patient selection, dosage, number of applications
• Comparative therapies: PRP has been similarly well researched in some indications and is partly equivalent
• Conclusion: BMAC is not a standard for everyone, but an option after careful consideration

Conservative therapy first

Before we recommend regenerative intervention, conservative treatment is the priority. This can often significantly reduce symptoms and is the basis of any sustainable therapy.

• Targeted physiotherapy and training therapy (strength, coordination, mobility)
• Adjustment to everyday life and stress, if necessary weight reduction
• Short-term pain and inflammation medication as needed and medically reviewed
• Orthosis/insoles, taping, ergonomic adjustments
• Shock wave therapy for tendinopathies (depending on the findings)
• Injection therapies with hyaluronic acid or PRP as alternative biological options

Process of the treatment in our practice (Hamburg)

Our location: Dorotheenstraße 48, 22301 Hamburg. We value structured preparation, sterile procedures and precise, image-guided injection techniques.

Requirements and exclusion criteria

Not every person is suitable for BMAC treatment. Before the procedure, we carefully check general and orthopedic requirements.

• Stable general health, no acute infection
• Adequate blood clotting; Anticoagulation must be checked individually and, if necessary, paused/adjusted in consultation with the prescribing doctor
• No local skin infections in the collection or injection area
• No known malignancies in the treated area; Oncological anamnesis is assessed separately
• Realistic expectations and willingness for active follow-up treatment (physiotherapy)
• Pregnancy/breastfeeding: generally not used

Risks and possible side effects

Like any intervention, BMAC carries risks. Serious complications are rare but cannot be ruled out. We will provide you with comprehensive information in advance.

• Pain, feeling of pressure or hematoma at the donor site (iliac crest)
• Temporary increase in pain in the treatment area
• Infection (very rare with sterile technology), impaired wound healing
• Nerve irritation, vascular injury (rare)
• General risks of minor procedures (e.g. circulatory reactions)
• Theoretical risks of insufficient effect; treatment success cannot be guaranteed

What can realistically be expected?

Many sufferers report – if the indication is right – gradual improvement within 4 to 12 weeks. The effect can begin subtly and increase with accompanying physical therapy. Depending on the findings, a single injection may be sufficient; in other cases, 1-3 applications at intervals of weeks to a few months are considered. Reliable success cannot be guaranteed.

Regulatory information and quality standards

In Germany, autologous bone marrow concentrate (BMAC) may be used as a minimally manipulated preparation as part of medical therapy. We do not perform cell culture with expansion. The treatment takes place under sterile conditions; Depending on the region, we use imaging techniques (ultrasound or x-ray) for placement in order to increase precision and safety.

Aftercare and rehabilitation

• protection on the day of treatment; local cooling as needed
• Relative relief for 24-48 hours, then gradual increase in load
• Avoiding intensive sports typically for 1-2 weeks (individual coordination)
• Targeted physiotherapy to optimize mobility, strength and neuromuscular control
• Medications: NSAIDs can affect inflammatory modulation; Take only after medical consultation

Costs and reimbursement

Treatment with bone marrow stem cells (BMAC) is usually a self-pay service. Billing is based on GOÄ (analog) and includes consultation, diagnostics, collection, preparation and injection. Statutory health insurance companies currently usually do not cover the costs; Private insurers reimburse depending on the tariff. Before any measure is taken, you will receive a transparent cost estimate.

Who is the method not suitable for?

• Acute infections, febrile illnesses
• Insufficient blood clotting or uncontrollable anticoagulation
• Severe, advanced osteoarthritis with significant structural destruction and misalignment (surgical procedures are often more effective here)
• Lack of willingness for active follow-up treatment
• Unclear tumor diseases or local malignant processes

Related regenerative processes and alternatives

Depending on the findings, other conservative or regenerative measures may also be considered. We will advise you which option makes sense in your situation.

• Adipose stem cells (ADF/MSC) – autologous stromal cells from adipose tissue
• Ear cartilage-based chondrocytes – cell therapy for selected cartilage lesions
• PRP (autologous blood plasma) – concentration of platelets and growth factors
• Hyaluronic acid – viscosupplementation for osteoarthritis
• Shock wave therapy – especially for tendinopathies